Mode
Text Size
Log in / Sign up
N/A N=10 Treatment

SleepFlexTM Treatment of Obstructive Sleep Apnea

Obstructive Sleep Apnea

Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Jun 2023
Primary outcome: Primary: Number of Participants With Freedom From SleepFlex-related Serious Adverse Events — 10 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
SleepFlex (Device)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
Berendo Scientific, LLC
Primary completion
Apr 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Freedom From SleepFlex-related Serious Adverse Events
10
PRIMARY
Change in the Apnea-hypopnea Index (AHI)
2.9
SECONDARY
Number of Participants With Development of Side Effects: Mouth, Throat, or Neck Pain; Dysphagia

Summary

The purpose of this study is to evaluate the safety and effectiveness of the SleepFlex program for treatment of mild to moderate OSA

Eligibility Criteria

Inclusion Criteria

  • Age 21 years and older
  • Mild to moderate OSA, defined as AHI >10 - 30 events/hour, documented by polysomnogram or home sleep apnea test within 180 days prior to study enrollment
  • Central or mixed disordered breathing events (≤25% of total number of events)
  • Unable to tolerate or decline positive airway pressure therapy
  • Body mass index ≤32 kg/m2
  • Able to protrude tongue ≥20 mm beyond maxillary incisors
  • Absence of markedly enlarged tonsils, defined as 3+ or 4+ according to the Brodsky classification
  • No uncontrolled sleep disorder other than OSA such as narcolepsy, chronic insomnia, restless legs syndrome, or REM behavior disorder
  • Absence of excessive daytime sleepiness, defined by Epworth Sleepiness Scale score >10
  • No uncontrolled nasal obstruction
  • Absence of moderate to severe mandibular insufficiency
  • No previous surgery involving the oral cavity or pharynx other than tonsillectomy
  • No previous radiation therapy to the head and neck
  • No known neurologic, cardiac (other than hypertension controlled with a single medication), pulmonary, renal, hepatic, or psychiatric disorders
  • No psychiatric diagnoses other than treated depression or mild anxiety
  • Stable medication regimen for ≥1 month
  • No acute illness or infection
  • Ownership of personal smartphone with iOS or Android operating system
  • No known hypersensitivity to any material of the SleepFlex devices

Exclusion Criteria

  • Unwilling or unable to provide informed written consent in English
  • Pregnancy, breastfeeding, or plans to become pregnant
  • Smoker (tobacco or recreational drugs) in the past month
  • Alcohol consumption, averaged over the previous month, greater than 2 alcoholic beverages per day
  • Significant vision or hearing problems
  • Unwilling or incapable of returning for all follow-up visits and conduct sleep studies at home, including the evaluation procedures and filling out questionnaires
  • Any other reason the investigator determines as being unfit for study participation
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04726514). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search